3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Breast
1
Conditions
Glioblastoma
5
Prostatic Neoplasms
4
Glioma
4
Lung Neoplasms
3
Epstein-Barr Virus Infections
3
Astrocytoma
3
Neoplasms
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia
2
Cytomegalovirus Infections
2
Breast Neoplasms
2
Wilms Tumor
1
Waldenstrom Macroglobulinemia
1
Uveal Melanoma
1
Triple Negative Breast Neoplasms
1
Testicular Neoplasms
1
Stomatitis
1
Sezary Syndrome
1
Recurrence
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pleural Effusion, Malignant
1
Pdgfra-Associated Chronic Eosinophilic Leukemia
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroblastoma
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Mycosis Fungoides
1
Multiple Myeloma
1
Interventions
Cisplatin
8
Carboplatin
8
Bevacizumab
8
Pleurodesis
7
Talc
6
Paclitaxel
6
Docetaxel
5
Povidone-Iodine
4
Doxycycline
4
Taxes
3
Gemcitabine
3
Drug Therapy
3
Chest Tubes
3
aldesleukin
2
Zoledronic Acid
2
Trastuzumab
2
Thoracoscopy
2
Sodium Chloride
2
Silver Nitrate
2
Pharmaceutical Preparations
2
Nivolumab
2
Interleukin-2
2
Fluorodeoxyglucose F18
2
Fentanyl
2
Erlotinib Hydrochloride
2
Cetuximab
2
Bortezomib
2
viscum album peptide
1
tocilizumab
1
tipifarnib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Pleural Effusion, Malignant
×
Valacyclovir
×
Clear all
NCT01997190
2023-08-25
MpeTK01
Candel Therapeutics, Inc.
Phase 1
Completed
19 enrolled